Durect Reports Positive Phase IIb Results For Posidur In Post-Op Hernia Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Posidur, co-developed with Nycomed, has the potential to become a more than $2 billion opportunity, Durect CFO tells “The Pink Sheet” DAILY.
You may also be interested in...
Remoxy NDA Set For Q2 Following Positive Phase III Results
Oradur technology could make the oxycodone product less susceptible to abuse and differentiate it in the market, Durect CEO Brown tells the DAILY.
Remoxy NDA Set For Q2 Following Positive Phase III Results
Oradur technology could make the oxycodone product less susceptible to abuse and differentiate it in the market, Durect CEO Brown tells the DAILY.
Durect and Nycomed To Collaborate On Anesthetic Posidur In $202 Mil. Deal
Durect expects to add 100 to 150 sales reps to market the drug in the U.S.